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Abstract
EVI1 has pleiotropic functions during murine embryogenesis and its targeted disruption leads to prenatal death by severely
affecting the development of virtually all embryonic organs. However, its functions in adult tissues are still unclear. When
inappropriately expressed, EVI1 becomes one of the most aggressive oncogenes associated with human hematopoietic and
solid cancers. The mechanisms by which EVI1 transforms normal cells are unknown, but we showed recently that EVI1
indirectly upregulates self-renewal and cell-cycling genes by inappropriate methylation of CpG dinucleotides in the
regulatory regions of microRNA-124-3 (miR-124-3), leading to the repression of this small gene that controls normal
differentiation and cell cycling of somatic cells. We used the regulatory regions of miR-124-3 as a read-out system to
investigate how EVI1 induces de novo methylation of DNA. Here we show that EVI1 physically interacts with DNA
methyltransferases 3a and 3b (Dnmt3a/b), which are the only de novo DNA methyltransferases identified to date in mouse
and man, and that it forms an enzymatically active protein complex that induces de novo DNA methylation in vitro. This
protein complex targets and binds to a precise region of miR-124-3 that is necessary for repression of a reporter gene by
EVI1. Based on our findings, we propose that in cooperation with Dnmt3a/b EVI1 regulates the methylation of DNA as a
sequence-specific mediator of de novo DNA methylation and that inappropriate EVI1 expression contributes to
carcinogenesis through improper DNA methylation.
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Introduction
Evi1 (Ecotropic virus integration 1) was identified as a common
locus of retroviral integration in susceptible mice leading to the
development of aggressive myeloid tumors [1]. The gene is highly
conserved through evolution with homologs identified in eukary-
otes from Xenopus to man [2]. In mouse and man the gene
encodes a nuclear protein of 1051 amino acids with two domains
of seven and three repeats of the zinc finger motif. In the mouse,
homozygous disruption of Evi1 leads to embryonic lethality (E10.5)
with widespread hypocellularity and disruption of the developing
organs [3], suggesting that this gene plays a critical role during
organogenesis and morphogenesis as well as in cellular prolifer-
ation and differentiation. The role of this gene in adult tissues is
less clear. Conditional deletion of Evi1 in adult murine HSCs leads
to a failure of their repopulating ability [4] whereas its forced
expression in HSC upregulates cell division and self-renewal [5].
In patients, the inappropriate activation of EVI1 is associated with
development or progression of myeloid leukemia [6,7] and solid
cancers [8–11]. In vitro studies have shown that EVI1 blocks the
TGF-beta [12] and the INF-alpha [13] pathways, and that
interacts with many transcription factors, including GATA1 [14],
RUNX1 [15], and PU.1 [16], presumably altering their functions.
Finally, EVI1 has the ability to interact with co-repressors and co-
activators of gene transcription [17].
DNA methylation, which occurs at the C5 position of a cytosine
residue, is a major form of epigenetic modification with a role in
gene silencing and genome stability [18]. Dense methylation of
promoters causes strong transcriptional repression [19]. Abnormal
DNA methylation, which often affects tumor suppressor genes, is
one of the most consistent epigenetic changes seen in cancers [20].
There are three known catalytically active DNA methyltransfer-
ases (DMTs) two of which, 3a and 3b, are de novo DMTs
(dnDMTs) [21]. The signals by which dnDMTs recognize and
target specific DNA sequences to be methylated are unknown.
Recently, we showed that EVI1 downregulates microRNA-124
(miR-124), a group of small genes that control differentiation and
cell cycling of normal hematopoietic cells [22]. We further
reported that the downregulation occurs through EVI1-induced
methylation of CpG dinucleotides located upstream of miR-124-3.
This de novo methylation leads to miR-124 repression and to the
upregulation of genes required for self-renewal and cell division
such as Bmi1 and Cyclin D3 that are regulated by miR-124 [22].
Here, we show that EVI1 physically interacts with dnDMTs and
that the two proteins form an enzymatically active complex that
cooperatively binds to specific regulatory regions of miR-124-3.
The proteins cooperate in repressing a reporter gene stably
integrated in a cell line and are capable of DNA methylation in
vitro. Based on our findings, we propose that EVI1 participates in
DNA methylation as a novel sequence-specific co-factor of de novo
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20793DNA methylation and that, when inappropriately expressed, alters
the differentiation status of a cell by improper methylation of
genes, ultimately leading to cell transformation.
Results
EVI1 requires the cooperation of Dnmt3b to efficiently
repress the regulatory region of miR-124-3
We previously reported that the expression of EVI1 in murine
HSC induces the upregulation of cell division and an enhance-
ment of self-renewal as a result of miR-124 silencing through DNA
methylation of miR-124 regulatory regions. MiR-124 regulates
these pathways [23]. We also reported that the EVI1 mutant
EVI1-(1+6Mut), which contains two point mutations in two zinc
finger motifs [14,22], does not significantly alter these pathways
and is unable to significantly methylate the regulatory regions of
miR-124-3 [22]. To evaluate the mechanism by which EVI1 can
induce methylation of DNA, we inserted the regulatory regions of
miR-124-3 between nucleotides 2467 and +28 upstream of the
Luciferase reporter gene and used this plasmid as a read-out
system. We also generated two additional reporter constructs that
contained the region between nucleotides 2340 and +28 and
between nucleotides 2109 and +28 (Figure 1A). To avoid artifacts
due to transient transfection of the reporter gene and to provide a
chromatin structure for the reporter gene, these plasmids were
stably integrated into NIH-3T3 cells. Multiclonal populations of
stably transfected NIH-3T3 cells were used to read the response of
the artificial promoter to effector plasmids (empty vector, EVI1,
EVI1-(1+6Mut), Dnmt3b, and EVI1+Dnmt3b). The results of the
reporter gene assays are shown in Figures 1B and 1C. Firstly, we
noted that when EVI1 was expressed by itself, it was able to
repress moderately (10% to 15%) the three artificial promoters
(Figure 1B). In contrast, when the mutant EVI1-(1+6Mut) was
expressed there was a positive response of the reporter gene
(Figure 1C). Because, as we will show later, this mutant does not
significantly bind to the artificial promoter or interact with
Dnmt3b, we believe that this upregulation could be caused by
effects similar to squelching and was not investigated further.
Secondly, we noted that Dnmt3b was unable to significantly
repress the promoter by itself (Figure 1B and 1C). Finally we
observed that there was a significant cooperative repressive effect
between EVI1 and Dnmt3b on the response of the reporter.
However, this increased repression was observed only when the
artificial promoter contained the 2467/2340 region (compare
the third bars in the three panels of Figure 1B), suggesting that this
short fragment is required for cooperation between EVI1 and
Dnmt3b. No cooperative repression was observed when EVI1-
(1+6Mut) was expressed with Dnmt3b (Figure 1C).
EVI1 interacts with Dnmt3a in vivo
It is generally accepted that proteins that cooperate in promoter
regulation often interact between themselves at the promoter site.
Therefore, to determine whether an interaction exists between
EVI1 and DNA methyltransferases, we used first transient
transfection of cell lines and co-IP assays with the wild type
EVI1 and the mutant EVI1 as a negative control. Exponentially
growing 293T cells were co-transfected with Dnmt3a alone or in
combination with either EVI1 or EVI1-(1+6Mut). Two days after
transfection, EVI1 and EVI1-(1+6Mut) were immunoprecipitated
with anti-HA antibody, which recognizes HA-tagged EVI1 and
EVI1-(1+6Mut), and the immunoprecipitated proteins were
separated by electrophoresis and analyzed by Western blot. As
shown in Figure 2A, Dnmt3a was co-precipitated by anti-HA
antibody in extracts of cells co-transfected with EVI1 (lane 7, top)
indicating that Dnmt3a interacts with EVI1 in vivo. In contrast, in
the absence of EVI1 (lane 6, top) or in the presence of EVI1
mutant (lane 8, top), the antibody was not able to co-precipitate
Dnmt3a significantly.
To confirm the results, we evaluated the interaction of EVI1
with endogenous dnDMTs using antibodies specific to Dnmt3a
and Dnmt3b. 293T cells were transfected with EVI1 and the
assays were performed as described above. As shown in Figures 2B
and 2C, EVI1 co-precipitates with endogenous Dnmt3a
(Figure 2B, lane 5) and Dnmt3b (Figure 2C, lane 5), suggesting
that EVI1 forms complexes with dnDMTs in vivo. In contrast,
EVI1-(1+6Mut), which does not induce miR-124-3 methylation in
vivo [22], did not bind to the dnDMTs in vivo (lane 6 in Figures 2B
and 2C). The interaction of endogenous EVI1 and Dnmt3a/
Dnmt3b was confirmed with endogenous proteins in K562 cells
(data not shown).
Zinc finger motifs 1 and 6 of EVI1 are required for
interaction with the catalytic domain of Dnmt3a
EVI1 is a complex protein that contains ten zinc finger motifs,
seven of which are closely grouped together at the N-terminus
(proximal zinc finger domain) and the remaining three motifs are
located at the C-terminus (distal zinc finger domain) (Figure 3A).
We earlier showed that the proximal zinc finger domain is crucial
for EVI1-induced methylation of DNA, which is not observed
when this domain is mutated in EVI1-(1+6Mut) [22]. Dnmt3a is
also a complex protein with several functional domains that have
been characterized (Figure 3A). To map the interaction between
the two proteins, we first tested full length EVI1 with each one of
the Dnmt3a domains. The analysis was carried out by transient
transfection of 293T cells and co-IP assays as described above. The
results indicate that the full length EVI1 preferentially interacts
with the C-terminus of Dnmt3a, which contains the catalytic
domain (Figure 3B, lane 10). Because the results shown in Figure 2
suggested that the proximal zinc finger domain of EVI1 could be
involved in the interaction, we tested the ability of this domain to
interact with Dnmt3a. We transfected 293T cells with the
proximal domain alone or in combination with domains of
Dnmt3a. The results of the Western blot analyses confirm that the
proximal domain of EVI1 interacts with the catalytic region of
Dnmt3a (Figure 3C, lane 10) and that mutation of zinc finger
motifs 1 and 6 abrogates the interaction (Figure 3D, compare top
lanes 8 and 9). Finally, to exclude the role of any other EVI1
regions in the interaction, we co-expressed an EVI1 mutant that
lacks the proximal zinc finger domain (EVI1-D7ZnF) with the
catalytic domain of Dnmt3a. The results confirm that the
interaction occurs through the proximal zinc finger domain and
that no other region of EVI1 significantly contributes to the
association between the two proteins (Figure 3D, compare top
lanes 8 and 10).
EVI1 and dnDMTs co-immunoprecipitate with the
genomic regulatory region of miR-124-3
We used ChIP assays to determine whether EVI1 and the
Dnmt3 proteins associate with the regulatory region of miR-124-3.
293T cells were transiently transfected with plasmids encoding
EVI1 or mutant EVI1-(1+6Mut) and processed as indicated in
Materials and Methods. The nuclear proteins associated with
chromatin were immunoprecipitated with HA antibody, which
recognizes the epitope-tagged EVI1 and mutant EVI1-(1+6Mut),
or with Dnmt3b antibody. As shown in Figure 4A, lanes 5 and 8,
an antibody to EVI1 or Dnmt3b efficiently co-precipitates a DNA
fragment from the regulatory region of miR-124-3 when EVI1 is
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region. In contrast, when EVI1 is absent or mutated, the Dnmt3b
antibody is unable to precipitate well the same fragment,
supporting the notion that EVI1 could have a role in directing
and efficiently binding the DNA methyltransferase to this DNA.
Similar ChIP results were obtained with antibody to Dnmt3a in
Figure 1. EVI1 synergizes with Dnmt3b to repress the regulatory regions of miR-124-3. A. Diagram of miR-124-3-Luciferase reporter gene.
Numbers indicate the nucleotide boundaries of the reporter constructs and they are numbered respect to the stem-loop start in the miR-124-3 gene
taken as +1 and indicated by the arrow. B, C. NIH-3T3 cells stably transfected with reporter plasmids (2467/+28 or 2340/+28 or 2109/+28) were
transiently co-transfected with effector plasmids as shown in the panels. Cell extracts were used for quantification of the reporter gene as described
in Material and Methods.
doi:10.1371/journal.pone.0020793.g001
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PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e20793Figure 2. EVI1 interacts with de novo DNA methyltransferases. A. EVI1 (lane 7) but not EVI1-(1+6Mut) (lane 8) interacts with Dnmt3a. 293T
cells were co-transfected with Myc-tagged Dnmt3a alone (lanes 2 and 6) or in combination with HA-tagged EVI1 or EVI1-(1+6Mut) (lanes 3 and 7, or
lanes 4 and 8, respectively). Two days after transfection cell lysates were collected and incubated with anti-HA beads (lanes 5 to 8) followed by IP. The
immunoprecipitated proteins (lanes 5 to 8) and proteins from the cell lysates (lanes 1 to 4) were separated by electrophoresis, transferred to a PVDF
membrane and probed as marked in the Figure. Lanes 1 and 5 represent the results with mock transfected cells. B, C. 293T cells were transfected with
a plasmid encoding EVI1 (lanes 2 and 5) or EVI1-(1+6Mut) (lanes 3 and 6). Lanes 1 and 4 represent mock-transfected cells. Two days after transfection
cell lysates were collected and incubated with anti-Dnmt3a (B) or anti-Dnmt3b (C) antibody (lanes 4 to 6) followed by IP. The immunoprecipitated
proteins (lanes 4 to 6) and proteins from cell lysates (lanes 1 to 3) were separated by electrophoresis, transferred to a PVDF membrane and probed as
marked in the Figure.
doi:10.1371/journal.pone.0020793.g002
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homology between the two DNA methyltransferases, Dnmt3a
associates with this DNA region when EVI1 is expressed
(Figure 4B). To confirm the qualitative ChIP results and to
quantify the chromatin immunoprecipitated by EVI1 or by EVI1
mutant in presence or absence of added Dnmt3a, we transiently
transfected 293T cells with EVI1 or EVI1-(1+6Mut) alone or in
combination with Dnmt3a, followed by ChIP assays and used
PCR for ChIP quantification. The results (Figure 4, C and D)
confirm the previous qualitative ChIP results and also show that
Dnmt3a significantly increases the interaction/strength between
EVI1 and chromatin (compare lanes 2 and 4 in Figures 4C and
4D). This effect is strongly reduced or not observed at all when the
EVI1 mutant is used. It is possible that EVI1-(1+6Mut) retains a
minimal affinity with the miR-124-3 regulatory elements either
directly or through unknown factor(s).
An EVI1-Dnmt3b complex interacts with a specific miR-
124-3 regulatory element
The results we have shown so far suggest first, that EVI1 and
Dnmt3b cooperate in the repression of the regulatory elements
of miR-124-3; second, that the DNA region between nucleotides
2467 and 2340 is necessary for repression; and third, that these
two proteins could form a complex with DNA regulatory
element(s) of miR-124-3. We used EMSA to confirm that the
proteins associate with miR-124-3 elements. We used two
probes: the 147 bp segment (between nucleotides 2467 to
2321) that is important for repression (Figure 1B), and a 252 bp
segment between nucleotides 2340 to 289. The probes were
end-labeled PCR fragments amplified from genomic DNA and
the nuclear extracts were obtained from transfected 293T cells as
described in Materials and Methods. The results, shown in
Figure 5, indicate that EVI1 and Dnmt3b, alone or co-expressed
Figure 3. The zinc finger motifs 1 and 6 of EVI1 are required for interaction with the catalytic domain of de novo DNA
methyltransferases. A. Schematic diagram of EVI1 and Dnmt3a shows the relevant domains analyzed in this study. B. EVI1 interacts with the
catalytic domain of Dnmt3a. 293T cells were transiently co-transfected with full-length EVI1 and each one of the Flag-tagged separate domains of
Dnmt3a as indicated, and analyzed as described in Figure 2. Lanes 1 to 5 show the expression of EVI1 (bottom panel) and Dnmt3a domains (top
panel) in the transfected cells. Lanes 6 to 10 show the proteins after IP with anti-EVI1 antibody. C. The proximal zinc finger domain of EVI1 interacts
with the catalytic domain of Dnmt3a. 293T cells were transiently co-transfected with the HA-tagged EVI1 proximal domain (7ZnF) and each one of the
Flag-tagged domains of Dnmt3a. The cells were processed and analyzed as described above. Lanes 1 to 5 show the expression of 7ZnF domain
(bottom panel) and Dnmt3a domains (top panel) in the transfected cells. Lanes 6 to 10 show the proteins after IP with anti-EVI1 antibody. The
proximal domain, 7ZnF, interacts only with Dnmt3a catalytic domain (lane 10). D. Zinc finger motifs 1 and 6 must be intact for interaction with
Dnmt3a. 293T cells were transiently co-transfected with the Flag-tagged catalytic domain of Dnmt3a alone (lanes 2 and 7) or in combination with the
HA-tagged 7ZnF domain (lanes 3 and 8) or with the mutant 7ZnF-(1+6Mut) domain (lanes 4 and 9) or with EVI1-D7ZnF (lanes 5 and 10). The proteins
in the cell extracts were analyzed by Western blot after co-IP with anti-HA antibody. Interaction is observed only when the intact proximal domain is
expressed (lane 8).
doi:10.1371/journal.pone.0020793.g003
EVI1 Is a Cofactor of dnDMTs
PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e20793in the cells, fail to interact with the longer 252 bp probe (right
panel). However, the results are quite different when we used the
probe corresponding to the DNA fragment important for
repression (left panel) in that they clearly indicate that the
147 bp probe interacts with proteins from the nuclear extracts.
Despite a high background of diffuse unspecific bands (lane 1),
EVI1 alone (lane 2) and especially in presence of added Dnmt3b
(lane 3) has a clear affinity for the 147 bp miR-124-3 probe.
Moreover, the addition of excess (506) cold 147 bp competitor
disrupted the complex between EVI1 and 147 bp probe whereas
506excess of 252 bp competitor had very limited effect on the
EVI1 and 147 bp probe interaction (data not shown). Several
DNA sequences have been reported as potential DNA binding
site of the proximal zinc finger domain of EVI1 [24,25].
However, we did not find any significant homology between the
published consensus and the 147 bp that form the DNA probe to
which EVI1/dnDMT bind (data not shown).
Dnmt3b and EVI1 form an enzymatically active complex
that methylates DNA in vitro
We previously reported that EVI1 induces DNA methylation in
vivo leading to miR-124 repression [22] and here we have shown
that EVI1 and Dnmt3b form a complex that interacts with a
regulatory region of miR-124-3 required for repression of a stably
integrated reporter gene. To determine whether this complex
possesses methyltransferase activity we used an in vitro DNA
methyltransferase assay. Because it was reported that murine ES
cells have relatively high expression of DNA methyltransferases
[26], we stably transfected ES cells with an empty vector or with a
vector encoding EVI1 or EVI1-(1+6Mut). Proteins in ES cell
lysates were immunoprecipitated with a-HA antibody that
recognizes the epitope-tagged EVI1 and EVI1-mutant. After
several washes, the anti-HA beads with the adsorbed proteins were
incubated with the target/substrate DNA (879 bp PCR fragment
containing the regulatory region of miR-124-3) in the presence of
Figure 4. EVI1 and de novo DNA methyltransferases occupy the regulatory region of miR-124-3. A. ChIP assay was performed with
chromatin fragments obtained from 293T cells transiently transfected with empty vector (lanes 1, 4, and 7), EVI1 (lanes 2, 5, and 8) and EVI1-(1+6Mut)
(lanes 3, 6, and 9). For the ChIP, we used IgG (lanes 1 to 3) or anti-HA (lanes 4 to 6) or anti-Dnmt3b (lanes 7 to 9) antibodies. Transfected EVI1 (lane 5,
lower panel) and endogenous Dnmt3b (lane 8, lower panel) are present together on the putative miR-124-3 promoter. In contrast, when EVI1 is not
expressed (lanes 4 and 7) or is mutated (lanes 6 and 9) Dnmt3b is less capable of binding to chromatin. Lanes 1–3 represent negative control with
unspecific IgG. B. Dnmt3a is also enriched at the putative miR-124-3 promoter in EVI1-transfected cells (lane 4). ChIP assay was performed with
chromatin fragments derived from 293T cells transiently transfected with EVI1. C. Cooperation between EVI1 and Dnmt3a in promoter occupancy.
293T cells were transiently transfected with the empty vector (lane 1), EVI1 and EVI1-(1+6Mut) alone (lanes 2 and 3) or in combination with Dnmt3a
(lanes 4 and 5). The cells were used for chromatin fragments isolation/ChIP with anti-HA antibody. Normal EVI1 and Dnmt3a are more efficient in ChIP
(compare lanes 2 and 4). D. ChIP quantification. The signal for cells transfected with the empty vector was arbitrarily taken as 1. Lanes numbering in C
and D is the same.
doi:10.1371/journal.pone.0020793.g004
EVI1 Is a Cofactor of dnDMTs
PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e207933H-Ado-Met, and the reaction mixture was processed as described
in Material and Methods. As shown in Figure 6A, there is no
significant
3H-methylation of the substrate when we used the
proteins immunoprecipitated from ES cells expressing the empty
vector (lane 1) or the vector encoding the mutant EVI1 (lane 3). In
contrast, when the proteins were immunoprecipitated from EVI1-
expressing ES cells, a strong band was detected (lane 2). We
repeated this assay with 293T cells transiently transfected with
EVI1 (lane 4), Dnmt3b (lane 5), or EVI1 and Dnmt3b (lane 6).
With these cells we observed a fainter but clear
3H-methylation
band when EVI1 (lane 4) or Dnmt3b (lane 5) were expressed
alone. The
3H-methylation band became much stronger when the
two proteins were co-expressed in the cells (lane 6), supporting the
data we obtained with ChIP and EMSA suggesting that the
proteins co-operate in binding to the DNA and in de novo DNA
methylation. Figure 6B shows the expression of EVI1 or EVI1-
(1+6Mut) in ES cells obtained by quantitative PCR (left panel) and
the expression of EVI1 and Dnmt3b in 293T cells obtained by
Western blot analysis (right panel).
Discussion
Since the identification of EVI1 over 20 years ago [1], the
inappropriate expression of this gene has been associated with very
aggressive hematopoietic cancers and especially with myelodys-
plastic syndromes (MDS) of patients in whom EVI1 is often
activated following a chromosomal rearrangement at chromosome
3 band q26 [27]. Several publications on the role of EVI1 in
hematopoietic diseases showed that this protein not only affects
factors that control normal hematopoiesis such as RUNX1,
GATA1, and PU.1 [14–16], but also deregulates two critical
signaling networks controlled by TGF-beta and IFN-alpha [12,13]
that influence cell growth and differentiation in the bone marrow.
Therefore, it was thought that the major role of EVI1 in
hematopoietic transformation was based on inappropriate inter-
actions with factors and cytokines that monitor cell growth and
differentiation in a way similar to that proposed for leukemia-
associated and hematopoiesis-specific factors such as RUNX1 or
GATA1 or PU.1 [28–30]. In the last few years, however, it was
clearly shown that EVI1 is also activated in several aggressive solid
cancers such as lung, colon, and breast cancers [8–11], which
occur in tissues normally controlled by alternative sets of
differentiation factors. These new reports raise the question of
the role of EVI1 in a normal cell versus a neoplastic cell in which
the gene is inappropriately expressed irrespective of the tissue of
origin. Very little is known about the normal role of EVI1 in a cell.
Perhaps the earliest clue of a potential normal function of EVI1
can be found in the description of murine embryos in which Evi1
had been targeted and disrupted by homologous recombination
[3]. In contrast to the phenotype of RUNX12/2 (or GATA12/
2, or PU.12/2) embryos, which showed precise and well defined
abnormalities mostly confined to developing hematopoietic
compartments [31–33], the defects induced by Evi1 disruption
were not only extended to virtually all the developing organs but
the disruption of Evi1 had also an impact on the overall cellularity
of the developing embryo [3], suggesting a pleiotropic, rather than
Figure 5. EVI1-Dnmt3b interact with the putative miR-124-3 promoter. 293T cells were transiently transfected with the empty vector (lanes
1 and 6), EVI1 (lanes 2 and 7), EVI1 and Dnmt3b (lanes 3 and 8) and Dnmt3b (lanes 4 and 9) and used for nuclear lysates isolation/EMSA assay. Two
end-labeled probes of 147 bp (left panel) and 252 bp (right panel) were used. No significant signal is observed with the longer 252 bp probe (right
panel). In contrast, a strong unspecific background is observed with the 147 bp probe (lane 1) or when exogenous Dnmt3b is expressed (lane 4). A
slower migrating band appears with EVI1 (lane 2) and is enhanced by the expression of exogenous Dnmt3b (lane 3).
doi:10.1371/journal.pone.0020793.g005
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during embryogenesis. We believe that a second clue about a
potential function of EVI1 was found in multiple publications
linking EVI1 to MDS and in the observation that MDS cells are
characterized by overall inappropriate DNA methylation.
We and others recently reported that indeed a link exists
between EVI1 and DNA methylation [22,34] and here we used
our previous finding as a basis to understand the molecular
mechanism by which EVI1 is capable of DNA modification. We
have specifically looked at the potential co-operation of EVI1 with
dnDMTs because dnDMTs are involved in de novo methylation of
DNA. The biochemical characteristics of dnDMTs have been
extensively studied during the last few years. In addition to the
dissection of the dnDMTs major functional domains [21], it was
reported that the proteins require the catalytically inactive isoform
Dnmt3L for maximum activity and substrate affinity [35] and for
periodic DNA methylation [36], that specific lysine methylation in
proteins such as histones leads to preferential DNA methylation of
these genes [37], and that active DNA demethylation is crucial for
epigenetic reprogramming and induced pluripotency [38,39].
Several potential mechanisms have been proposed for DNA
methylation by dnDMTs including their interaction with unknown
factors, selective anchoring of dnDMTs on methylated nucleo-
somes [40], cooperation with lysine demethylases [41] or
methyltransferases [42,43], interaction with centromere proteins
[44], and association with sequence-specific DNA binding proteins
[45–47]. Interestingly, though, there is limited information
available on the identity of factors that allow recognition of target
DNA and on the precise mechanisms or the nature of the signals
required for specific CpG methylation. The results that we present
in this report using the regulatory region of miR-124-3 as a read-
out system suggest that EVI1 forms a complex with dnDMTs that
binds to specific regions of DNA and that is capable of CpG
methylation. Our data also suggest that these two events,
recognition of target DNA and CpG methylation by dnDMTs,
require EVI1 for optimal efficiency. Therefore, these results also
suggest a novel role of EVI1 as a critical co-factor in a complex
that methylates DNA. A question that is not answered here is how
EVI1 recognizes the DNA to which it binds in cooperation with a
dnDMT. We did not find any significant homology between the
published DNA consensus sites for EVI1 and any region of the
probe we used, suggesting that either EVI1 recognizes a previously
uncharacterized sequence, or recognizes a DNA/chromatin
structure rather than a naked, linear bp sequence, or that the
cooperation of another protein, in this case Dnmt3b, is necessary
to provide a multiprotein surface for recognition and interaction
with the DNA. At this time we do not have sufficient data to point
at the correct mechanism at the exclusion of the other possibilities
listed here. However, our eletrophoretic mobility shift assays show
that transfected EVI1 weakly binds to the probe when only
endogenous Dnmt3 proteins are present in the extract and that
Dnmt3b by itself does not significantly affect the probe migration.
In contrast, a band appears when both proteins are strongly co-
expressed, suggesting that the DNA recognition and binding could
be mediated by combined domains of the two proteins rather than
by a single-protein domain.
Since the understanding of the nature of EVI1 as an oncogene
when inappropriately expressed, there has been much emphasis to
unravel the tissue-specific pathways that this protein disrupts in a
transformed cell. Several years ago, we showed that endogenous
Evi1 is active in undifferentiated murine embryonic stem cells and
that it is slowly silenced during the differentiation of the cells in vitro
until is completely repressed in terminally differentiated cells [50],
suggesting a potential role in epigenetic establishment of gene
expression patterns during the transition of the cells from a
pluripotent phenotype to a lineage-committed state. These older
data together with the description of the Evi12/2 embryo, the
link between EVI1 and DNA methylation, and our data presented
Figure 6. EVI1 and de novo DNA methyltransferases form an enzymatically active complex. A. ES cells stably transfected with the empty
vector (lane 1), EVI1 (lane 2) or EVI1-(1+6Mut) (lane 3) were used for in vitro DMTase assay as described in Material and Methods. 293T cells were
transiently transfected with plasmids encoding EVI1 (lane 4), Dnmt3b (lane 5), or EVI1 and Dnmt3b (lane 6), and the IP proteins were used for in vitro
DMTase assay. A strong band evident in lane 2 represents the DNA methyltransferase activity of EVI1 and endogenous dnDMTs from ES cells. A strong
band evident in lane 6 results from the activity of co-transfected Dnmt3b and EVI1. B. Quantitative RT-PCR shows that the expression of EVI1 (lane 2)
and EVI1-(1+6Mut) (lane 3) in ES cells is comparable. Western blot analysis shows the expression of EVI1 (lane 4), Dnmt3b (lane 5) and EVI1+Dnmt3b
(lane 6) in 293T cells used for in vitro DMTase assay.
doi:10.1371/journal.pone.0020793.g006
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tissue- or lineage-specific but rather that is actively played in all
cells as a dominant participant in de novo DNA methylation. It has
long been known that abnormal DNA methylation is a hallmark of
many cancers [20] though the mechanism of this process is
unknown. Based on the data we present here, on our previously
published work [17,48,49], and on the work by Hoyt et al [3], we
would like to propose a novel role of EVI1 as a global player in
DNA modification, rather than solely as a lineage- or tissue-
specific oncogene, which acts as a co-factor in protein complexes
that regulate DNA and chromatin modifications both during
normal embryogenesis and in solid and hematopoietic cancers
when the gene is inappropriately activated.
Materials and Methods
DNA plasmids
The EVI1 plasmids used in this study have been described [14].
The EVI1 point mutant EVI1-(1+6Mut) contains the H39A and
C44A mutations in the first zinc finger and the C190A and C193A
mutations in the sixth zinc finger. Murine Dnmt3a fragments were
amplified by PCR and cloned with a Flag epitope into the pCMV
Vector (Invitrogen/Gibco) using a plasmid encoding Dnmt3a-Myc
as template. The latter plasmid and Dnmt3b-Myc are a generous
gift of Dr. Chih-Lin Hsien (University of Southern California, Los
Angeles). The murine miR-124-3 regulatory region between nt
2467 to +28 (where +1 corresponds to the stem-loop start site of
miR-124-3) was amplified by genomic PCR and cloned in the
promoterless luciferase reporter plasmid pGL4.20 (Promega). All
amplified DNA fragments were verified by DNA sequencing.
Cell infection and transfection
To generate infectious retrovirus particles, we transfected 20 mg
of plasmid/10 cm plate in the packaging GP2-293T cells
(Clontech) with MegaTrans 1.0 reagent (OriGene). DNA-
transfection of adherent cells was performed by the calcium
phosphate precipitation method. Murine ES cells were electropo-
rated by using Amaxa Nucleofector II system (Amaxa Biosystems)
and were cultured for 10 days in G418 to select those cells in
which the plasmid had integrated in the genome.
Cell culture
293T (ATCC number CRL-11268) and NIH-3T3 (ATCC
number CRL-1658) cell lines were maintained as described [51].
Murine ES cells (ATCC number CRL-1934) were maintained in
10 cm gelatin-coated plates in DMEM supplemented with 10%
FBS, 2 mM L-Glutamine, 1 mM MEM NEAA, 1 mM Sodium
Pyruvate, 500 mM 2-Mercaptoethanol and 10 ng/ml LIF.
Reporter gene studies
The reporter gene assays were performed with NIH-3T3 cells
stably transfected with a plasmid expressing the reporter gene
under the control of regulatory regions of miR-124-3. The regions
used are: 2467 to +28, or 2340 to +28, or 2109 to +28, where +1
corresponds to the stem-loop start site of miR-124-3. Stably
transfected NIH-3T3 cells were transiently co-transfected with
effector plasmids. After 72 h, equal numbers of cells were lysed
and analyzed. All measurements were done in triplicate.
Western blot analysis and immunoprecipitation (IP)
assays
Cells were harvested 48 h after transfection and treated as
described [51]. We used murine mAb M2 to the Flag epitope
(Sigma), rat mAb to the HA epitope (Roche), polyclonal rabbit
Ab to EVI1 and murine mAb 9B11 to Myc (Cell Signaling
Technology), and murine mAbs 64B1446 to Dnmt3a and
52A1018 to Dnmt3b (Imgenex).
Electrophoretic mobility shift assay (EMSA)
293T cells were transiently transfected with the necessary
plasmids and nuclear extracts were used for EMSA.
32P end-
labeled probes were 147 bp and 252 bp long, corresponding to the
2467/2321 and 2340/289 fragments of the miR-124-3 gene.
Binding assays were carried out in a 10 ml volume of 10 mM Tris-
HCl pH 7.5, 150 mM NaCl, 12.5% glycerol, 5 mM EDTA,
5 mM DTT, and poly-dI:dC (1 mg/reaction).
32P end-labeled
probes were added after 10 min and incubation was continued for
additional 20 min. The samples were loaded on 0.56Tris-borate-
EDTA nondenaturing 4% polyacrylamide gel, electrophoresed at
100 V for 3 h at 4uC, and autoradiographed overnight.
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed with transiently transfected 293T
cells by using SimpleChIP
TM Enzymatic Chromatin IP Kit (Cell
SignalingTechnology)accordingtothemanufacturer’sinstructions.
The DNA fragments were analyzed by PCR using two primers (59-
ggagaagtgtgggctcctc-39 and 59-aatcaaggtccgctgtgaac-39) designed to
amplify 222-bp of the miR-124-3 regulatory region.
In vitro DNA methyltransferase assays
An 879 bp PCR fragment (2851/+28) derived from miR-124-3
was used as a substrate. EVI1-Dnmt3a/b complexes from ES cells
or 293T cells were obtained by immunoprecipitation of the
proteins with anti-HA beads. Washed beads (15 ml) were
incubated with S-[methyl-
3H]-adenosylmethionine (Ado-Met)
(Perkin Elmer) in presence of the DNA substrate in 50 mM
Tris-HCl buffer pH 7.5, 2 mM DTT, 1 mM EDTA, and 0.1%
NP-40 in a volume of 30 ml for 24–48 h at 37uC. The incubation
mixtures were separated on 6% 0.56Tris-borate-EDTA non-
denaturing polyacrylamide gel, transferred onto a positively
charged nylon membrane (Roche), and exposed to a film for 2
weeks.
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